Immunogenicity of a Third Dose of Either the Moderna COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond After Two Previous Doses
The study investigates the immunogenicity of a third dose of mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) in kidney transplant recipients who exhibited inadequate antibody responses after two doses. Given the increasing recognition of vulnerable populations, such as transplant recipients, this research addresses a critical gap in COVID-19 vaccination strategies. The results could inform future vaccine recommendations and potentially expand market opportunities for mRNA vaccine manufacturers. The competitive landscape includes ongoing studies by other institutions focusing on similar populations, which may influence market positioning and pricing strategies. Diligence should consider the regulatory landscape and potential for expanded indications based on study outcomes.
Indication: Kidney Transplant Recipients
Modality: vaccine
Target: SARS-CoV-2 Spike Protein (Receptor Binding Domain)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 02, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SARS-CoV-2 Spike Protein (Receptor Binding Domain)
View original source fields
Condition raw: Kidney Transplant Recipients
Condition normalized: Kidney Transplant Recipients
Modality raw: vaccine
Modality normalized: vaccine
Target raw: SARS-CoV-2 Spike Protein (Receptor Binding Domain)
Target normalized: SARS-CoV-2 Spike Protein (Receptor Binding Domain)